Does malignancy status effect outcomes in patients with large vessel occlusion stroke and cancer that underwent endovascular thrombectomy?

Background: Cancer is associated with an increased risk of acute ischemic stroke (AIS) including large vessel occlusions (LVO). Whether cancer status affects outcomes in patients with LVO that undergo endovascular thrombectomy (EVT) remains unknown. Methods and Results: All consecutive patients undergoing EVT for LVO were recruited into a prospective ongoing multi-center database and the data was retrospectively analyzed. Patients with active cancer were compared to patients with cancer in remission. Association of cancer status with 90-day functional outcome and mortality were calculated in multivariable analyses. We identified 154 patients with cancer and LVO that underwent EVT (mean age 74{+/-}11, 43% men, median NIHSS 15). Of the included patients, 70 (46%) had a remote history of cancer or cancer in remission and 84 (54%) had active disease. Outcome data at 90 days post-stroke was available for 138 patients (90%) and was classified as favorable in 53 (38%). Patients with active cancer were younger and more often smoked but did not significantly differ from those without malignancy in other risk factors, stroke severity, stroke subtype or procedural variables. Favorable outcome rates among patients with active cancer did not significantly differ compared to those seen in patients without active cancer but mortality rates were significantly higher among patients with active cancer on univariate and multivariable analyses. Conclusions: Our study suggests that EVT is safe and efficacious in patients with history of malignancy as well as in those with active cancer at the time of stroke onset although mortality rates are higher among patients with active cancer.

[1]  A. Dmytriw,et al.  Outcomes after endovascular thrombectomy for acute ischemic stroke patients with active cancer: A systematic review and meta-analysis , 2022, Frontiers in Neurology.

[2]  S. Mayer,et al.  Investigating Outcomes Post–Endovascular Thrombectomy in Acute Stroke Patients With Cancer , 2022, Neurology.

[3]  S. Galetta,et al.  Editors' Note: Clinical Outcome After Endovascular Treatment in Patients With Active Cancer and Ischemic Stroke: A MR CLEAN Registry Substudy , 2022, Neurology.

[4]  T. Bhalla,et al.  Endovascular Therapy is Effective for Large Vessel Occlusion Despite Concurrent Cancer. , 2022, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[5]  R. Dafer,et al.  Endovascular thrombectomy for acute ischemic stroke in patients with cancer: a propensity-matched analysis , 2021, Journal of NeuroInterventional Surgery.

[6]  A. Demchuk,et al.  Assessment of Discrepancies Between Follow-up Infarct Volume and 90-Day Outcomes Among Patients With Ischemic Stroke Who Received Endovascular Therapy , 2021, JAMA network open.

[7]  S. Meletti,et al.  Efficacy of mechanical thrombectomy in patients with ischemic stroke and cancer , 2021, Journal of Clinical Neuroscience.

[8]  P. Myint,et al.  Prognosis of Acute Ischaemic Stroke Patients with Cancer: A National Inpatient Sample Study , 2021, Cancers.

[9]  Han-Yeong Jeong,et al.  Effectiveness of mechanical thrombectomy in cancer-related stroke and associated factors with unfavorable outcome , 2021, BMC Neurology.

[10]  V. Pereira,et al.  Endovascular therapy of acute ischemic stroke in patients with large-vessel occlusion associated with active malignancy. , 2020, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[11]  M. Giacca,et al.  Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. , 2020, Cardiovascular research.

[12]  B. Kim,et al.  Mechanical thrombectomy in patients with acute cancer-related stroke: is the stent retriever alone effective? , 2020, Journal of NeuroInterventional Surgery.

[13]  N. Chao,et al.  Endothelial cell function and endothelial‐related disorders following haematopoietic cell transplantation , 2020, British journal of haematology.

[14]  K. D. Castle,et al.  Establishing the Impact of Vascular Damage on Tumor Response to High-Dose Radiation Therapy. , 2019, Cancer research.

[15]  S. Kwon,et al.  Intra-arterial thrombectomy for acute ischaemic stroke patients with active cancer , 2019, Journal of Neurology.

[16]  M. Aschner,et al.  Cancer-associated stroke: Pathophysiology, detection and management (Review) , 2019, International journal of oncology.

[17]  E. Yeh,et al.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. , 2017, Journal of the American College of Cardiology.

[18]  M. Rezaei,et al.  Collateral Damage Intended—Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy , 2017, International journal of molecular sciences.

[19]  A. Demchuk,et al.  Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials , 2016, The Lancet.

[20]  S. Rosen,et al.  Cardiovascular toxicity of biologic agents for cancer therapy. , 2014, Oncology.

[21]  Joanna M. Wardlaw,et al.  Recommendations on Angiographic Revascularization Grading Standards for Acute Ischemic Stroke: A Consensus Statement , 2013, Stroke.

[22]  W. Struhal,et al.  Stroke and cancer: a review , 2009, Acta neurologica Scandinavica.

[23]  C. Enzinger,et al.  Poor short-term outcome in patients with ischaemic stroke and active cancer , 2015, Journal of Neurology.

[24]  P Trouillas,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.